Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders.
Synendos Therapeutics has raised €19M across 1 funding round from 2 investors, most recently a Series A round in Nov 2020. Based in Allschwil, Switzerland; founded 2019; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-11-12 | Series A |
| €19M |
| Kurma Partners,Sunstone Life Science Ventures |
| View deal → |
